Paragon 28, Inc. (FNA)
NYSE: FNA · IEX Real-Time Price · USD
7.66
-0.31 (-3.89%)
May 17, 2024, 4:00 PM EDT - Market closed
Paragon 28 Revenue
Paragon 28 had revenue of $225.44M in the twelve months ending March 31, 2024, with 17.38% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $61.08M with 17.38% year-over-year growth. In the year 2023, Paragon 28 had annual revenue of $216.39M with 19.30% growth.
Revenue (ttm)
$225.44M
Revenue Growth
+17.38%
P/S Ratio
2.82
Revenue / Employee
$392,744
Employees
574
Market Cap
635.41M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 216.39M | 35.01M | 19.30% |
Dec 31, 2022 | 181.38M | 33.92M | 23.00% |
Dec 31, 2021 | 147.46M | 36.48M | 32.87% |
Dec 31, 2020 | 110.98M | 4.70M | 4.42% |
Dec 31, 2019 | 106.28M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pharming Group | 280.83M |
Definitive Healthcare | 255.69M |
Weave Communications | 178.08M |
Zymeworks | 50.46M |
EyePoint Pharmaceuticals | 50.02M |
FNA News
- 10 days ago - Paragon 28 Reports First Quarter 2024 Financial Results and Reaffirms 2024 Net Revenue Guidance - Business Wire
- 16 days ago - Paragon 28 to Present at the Bank of America Securities 2024 Healthcare Conference - Business Wire
- 6 weeks ago - Appointment of Stephen M. Deitsch as new Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - NeuroStreet To Transform Trading Technology With Tickblaze Acquisition - Business Wire
- 6 weeks ago - Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024 - Business Wire
- 7 weeks ago - Paragon 28 Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler® R3INFORCE™ Extraosseous Repair System - Business Wire
- 2 months ago - Paragon 28 Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Net Revenue Guidance - Business Wire
- 3 months ago - Paragon 28 to Present at the CG 2024 Musculoskeletal Conference - Business Wire